| Literature DB >> 29985949 |
Jason R Gantenberg1, Maximilian King1, Madeline C Montgomery2, Omar Galárraga3, Mattia Prosperi4, Philip A Chan2, Brandon D L Marshall1.
Abstract
OBJECTIVES: Identifying prescribing strategies that improve the efficiency of PrEP should increase its impact at the population level. This study identifies PrEP allocation criteria that most effectively reduce 10-year HIV incidence by 25%, in accordance with the US National HIV/AIDS Strategy's goal for the proportionate reduction in new diagnoses.Entities:
Mesh:
Year: 2018 PMID: 29985949 PMCID: PMC6037355 DOI: 10.1371/journal.pone.0199915
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Overview of model parameters and processes.
| Processes | Provenance | Sources |
|---|---|---|
| Population size | Rhode Island | [ |
| Age (15–74) | Rhode Island | [ |
| Background mortality | Rhode Island | [ |
| Condom use | External | [ |
| Sexual role | External | [ |
| Annual partner number | Rhode Island | [ |
| Sex frequency | External | [ |
| Relationship duration | External | [ |
| Assortative mixing | External, Assumed | Based on [ |
| Testing probability | Rhode Island, calibrated | Starting probability from [ |
| Proportion of PLWH | Rhode Island | [ |
| Proportion of PLWH on ART | Rhode Island | Calculated, [ |
| Proportion of PLWH virally suppressed | Rhode Island | [ |
| Proportion of PLWH currently with AIDS | Rhode Island | Inferred, based on [ |
| Transmission probability by sexual position | External | [ |
| Transmission risk reduction due to HIV | Assumed | Assumed |
| Transmission risk reduction due to viral | External | [ |
| HIV prevalence (age-specific) | Rhode Island | [ |
| HIV/AIDS-related mortality rate ratio | External, Rhode Island | [ |
| Dropout rate | Rhode Island | [ |
| Adherence probability (full vs. partial) | Rhode Island | [ |
| HIV transmission risk reduction conferred | External | [ |
PLWH, people living with HIV; PrEP, pre-exposure prophylaxis; ART, antiretroviral therapy. Parameters, their values, and their sources are discussed in more detail in S1 Appendix.
Ten-year summary statistics across PrEP allocation scenarios (15% coverage) vs. base case (0% PrEP coverage).
| Scenario | HIV Prevalence (%) | New Infections | Incidence Rate | Infections Averted (#) | Infections Averted (%) | PYPAI |
|---|---|---|---|---|---|---|
| No PrEP | 7.4 | 826 | 3.51 | - | - | - |
| Current patients | 6.5 | 612 | 2.59 | 218 | 26.2 | 161 |
| Random | 6.7 | 654 | 2.77 | 176 | 21.2 | 199 |
| PN > 5 | 6.5 | 595 | 2.52 | 235 | 28.3 | 150 |
| PN > 10 | 6.3 | 555 | 2.35 | 275 | 33.1 | 128 |
Notes: HIV Prevalence, ending HIV prevalence; PYPAI, person-years on PrEP per averted infection; Current patients, Current Patient Population scenario; PN > 5, expected annual partner number greater than 5; PN > 10, expected annual partner number greater than 10. Medians and 95% simulation limits presented.
* Incidence rate per 1000 person-years at risk.
Fig 1Distribution of NIA (number of infections averted) estimates produced by 1000 independent simulations for each PrEP allocation scenario.
Mean cumulative incidence in base case scenario used as reference to calculate NIA. Dashed line, null effect of PrEP; Dotted line, 25% reduction in cumulative incidence. Negative values indicate individual PrEP scenario runs in which cumulative incidence exceeded the mean cumulative incidence in the No PrEP scenario. (Note: The PN > 10 allocation scenario covered a maximum of approximately 15–17% of the HIV-uninfected population. PrEP coverage scenarios between 20% and 30% should be interpreted with this ceiling coverage in mind when comparing allocation criteria against one another).
Fig 2Median person-years on PrEP per averted infection (PYPAI) by PrEP coverage target and actual achieved PrEP coverage across each of the allocation scenarios.
Achieved PrEP coverage refers to the actual simulated proportion of all HIV-uninfected MSM on PrEP for each coverage and allocation scenario. Because PYPAI outcome distributions were heavily right-skewed at lower PrEP coverages—due in part to how the measure was penalized to account for runs in which PrEP scenarios featured more infections than the mean base case—simulation intervals are omitted to avoid overplotting.
Sex frequency and partner number sensitivity analyses.
HIV prevalence and incidence at 0% PrEP coverage.
| Scenario | HIV | Cumulative Incidence | Incidence Rate | Incidence Change (%) |
|---|---|---|---|---|
| Main | 7.4 | 826 | 3.51 | - |
| SF0.5 | 4.5 | 294 | 1.23 | -64.3 |
| SF1.5 | 11.9 | 1756 | 7.65 | 112.6 |
| PN0.5 | 5.2 | 389 | 1.63 | -52.9 |
| PN1.5 | 24.1 | 4487 | 20.88 | 443.2 |
Notes:
Main, base case from main analysis
SF[X], sex frequency scale
PN[X], partner number scale
HIV Prevalence, ending HIV prevalence; CumInc, new infections over 10 years; IR, incidence rate per 1000 person-years at risk
Incidence change = percent change in 10-year median cumulative incidence relative to Main scenario
Medians and 95% simulation limits reported
* Omits 62 runs for which submitted jobs timed out (N = 938 independent simulations). All other results based on 1000 independent simulations for each scenario.
Fig 3HIV incidence rates, PIA, and PYPAI by population sex frequency scenario.
Each scenario scaled sex frequency by the factors depicted in the images. In the top row, lines encode means at each year. In the bottom row, the dashed line and purple band indicate the median and 95% simulation interval in the Current Patients PrEP allocation scenario at 15% coverage. Point ranges depict these statistics for the alternative sex frequency scenarios, also at 15% PrEP coverage. Abbreviations: IR, incidence rate per 1000 person-years at risk; PIA, percentage of infections averted; PYPAI, person-years per averted infected.
Sex frequency, partner number, and PrEP adherence sensitivity analyses.
PrEP impact and efficiency at 15% coverage of HIV-negative MSM.
| Scenario | NIA | PIA | PYPAI |
|---|---|---|---|
| Main | 218 | 26.2 | 161 |
| SF0.5 | 68 | 22.9 | 527 |
| SF1.54 | 520 | 29.6 | 66 |
| PN0.5 | 89 | 22.7 | 401 |
| PN1.5 | 1471 | 32.8 | 23 |
| Adh0.00 | 190 | 22.9 | 185 |
| Adh0.50 | 202 | 24.4 | 174 |
| Adh1.00 | 221 | 26.6 | 159 |
Notes:
Main, base case from main analysis
SF[X], sex frequency scale
Adh[X], proportion of PrEP agents fully adherent (remainder are partially adherent in all cases)
PrEP, pre-exposure prophylaxis; MSM, men who have sex with men; NIA, number of infections averted, PIA, percentage of infections averted; PYPAI, person-years per averted infection
Medians and 95% simulation limits reported
* Omits 40 runs for which submitted jobs timed out (N = 960 independent simulations). All other results based on 1000 independent simulations for each scenario.
Fig 4NIA and PYPAI measures by PrEP adherence scenario.
Each scenario altered the proportions of individuals on PrEP who were fully vs. partially adherent (0/100, 50/50, 100/0, respectively). In the main analysis, 82% of current PrEP patients were considered to be fully adherent. NIA, number of infections averted; PYPAI, person-years per averted infection. The dashed line and purple band indicate the median and 95% simulation interval in the Current Patients PrEP allocation scenario at 15% coverage. Point ranges indicate these same statistics for the alternative PrEP adherence scenarios, also at 15% coverage.